Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cells ; 19(6): 514-21, 2001.
Article in English | MEDLINE | ID: mdl-11713343

ABSTRACT

Leridistim, a member of the myelopoietin family of dual receptor agonists that binds interleukin-3 and G-CSF receptors, has been shown to enhance hematopoietic activity in rhesus monkeys above that observed with either cytokine alone or in combination. This study demonstrated the ability of a pegylated form of leridistim (peg-leridistim), administered s.c., as a single- or two-dose regimen separated by 4 or 7 days, to significantly improve neutrophil recovery following radiation-induced myelosuppression. Rhesus macaques were total body x-irradiated (250 kVp, TBI) to 600 cGy. Following TBI, two groups received peg-leridistim (n = 5) or leridistim (n = 4) at a dose of 600 microg/kg on day 1, while two other groups (both n = 4) received peg-leridistim at 200 microg/kg on day 1 and day 4, or day 1 and day 7. The irradiation controls (n = 7) received 0.1% autologous serum for 18 days. All peg-leridistim treatment schedules significantly improved all neutrophil-related parameters following TBI as compared with nontreated controls and were equivalent in effect when compared among themselves. Administration of a single high dose or two separate lower doses of peg-leridistim significantly improved neutrophil regeneration, in a manner equal to that of conventional daily or abbreviated every-other-day administration of leridistim in this nonhuman primate model of severe myelosuppression.


Subject(s)
Granulocyte Colony-Stimulating Factor , Interleukin-3/pharmacology , Neutropenia/prevention & control , Neutrophils/drug effects , Animals , Bone Marrow Cells/drug effects , Bone Marrow Cells/radiation effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Hematopoietic Stem Cells/drug effects , Hematopoietic Stem Cells/radiation effects , Interleukin-3/chemistry , Interleukin-3/pharmacokinetics , Macaca mulatta , Male , Metabolic Clearance Rate , Neutropenia/etiology , Neutropenia/pathology , Neutrophils/cytology , Neutrophils/radiation effects , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Polyethylene Glycols/pharmacology , Radiation Dosage , Recombinant Fusion Proteins , Recombinant Proteins , Time Factors , Whole-Body Irradiation/adverse effects
2.
Exp Hematol ; 27(12): 1746-56, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10641592

ABSTRACT

A combinatorial mutagenesis strategy was used to create a collection of nearly 500 variants of human interleukin 3 (IL-3), each with four to nine amino acid substitutions clustered within four linear, nonoverlapping regions of the polypeptide. The variants were secreted into the periplasm of Escherichia coli and supernatants were assayed for IL-3 receptor-dependent cell proliferation activity. Sixteen percent of the variants, containing "region-restricted" substitutions, retained substantial proliferative activity through two rounds of screening. A subset of these was combined to yield variants with substitutions distributed through approximately half of the polypeptide. With one exception, "half-substituted" variants exhibited proliferative activity within 3.5-fold of native IL-3. A subset of the "half-substituted" variants was combined to yield "fully substituted" IL-3 variants having 27 or more substitutions. The combination of the substitutions resulted in a set of polypeptides, some of which exhibit increased proliferative activity relative to native IL-3. The elevated hematopoietic potency was confirmed in a methylcellulose colony-forming unit assay using freshly isolated human bone marrow cells. A subset of the multiply substituted proteins exhibited only a modest increase in inflammatory mediator (leukotriene C4) release. The molecules also exhibited 40- to 100-fold greater affinity for the alpha subunit of the IL-3 receptor and demonstrated a 10-fold faster association rate with the alpha-receptor subunit. The multiply substituted IL-3 variants described in this study provide a unique collection of molecules from which candidates for clinical evaluation may be defined and selected.


Subject(s)
Interleukin-3/genetics , Interleukin-3/pharmacology , Amino Acid Substitution , Humans , Interleukin-3/chemistry , Mutagenesis , Protein Engineering , Structure-Activity Relationship
3.
J Biol Chem ; 270(40): 23754-60, 1995 Oct 06.
Article in English | MEDLINE | ID: mdl-7559548

ABSTRACT

A deletion variant of human interleukin-3, hIL-3(15-125), was produced in the periplasmic space of Escherichia coli and had full activity in an AML193.1.3 cell proliferation assay. Libraries of random single-amino acid substitutions were constructed at each of 105 positions in the gene for hIL-3(15-125). Approximately eight single-site substitutions at each position were produced in osmotic shock fractions and screened for activity. 15 mutants were found with bioactivity of 5-26-fold greater than that of native hIL-3. The majority of amino acids in hIL-3(15-125) could be substituted without substantial loss of activity. Substitution of residues predicted to be in the hydrophobic core of the protein often resulted in reduced activity and/or low accumulation levels. Only five residues predicted to be on the surface of the protein were intolerant of substitution and hence are candidates for sites of interaction with the receptor. We therefore propose that the majority of residues in hIL-3 serve a structural role and permit the display of a few key residues in the correct configuration for recognition by the receptor.


Subject(s)
Interleukin-3/genetics , Mutagenesis , Amino Acid Sequence , Base Sequence , Cell Division/drug effects , Cell Line , DNA Primers/genetics , Escherichia coli/genetics , Humans , Interleukin-3/chemistry , Interleukin-3/pharmacology , Molecular Sequence Data , Molecular Structure , Mutagenesis, Site-Directed , Point Mutation , Protein Structure, Secondary , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Sequence Deletion , Structure-Activity Relationship
4.
Article in English | MEDLINE | ID: mdl-10246871

ABSTRACT

This study investigated current perceptions of a sample of unionized and non-unionized physicians toward the concept of collective bargaining. Specific areas for study were the issues that have motivated and might motivate physicians to unionize, as well as the individuals or institutions physicians perceive as the opponent in collective bargaining. The analysis showed that economic considerations and the imposition of external controls on the practice of medicine dominate the physicians' perceptions. Government and health insurance companies are perceived as the primary adversaries. Perceptual differences between unionized and non-unionized physicians were shown to be small.


Subject(s)
Attitude of Health Personnel , Collective Bargaining , Labor Unions , Physicians/psychology , Humans , Motivation , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...